证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-021 迪瑞医疗科技股份有限公司 2024 年年度权益分派实施公告 4、本次分红派息距离股东大会通过利润分配方案时间未超过两个月。 二、本次实施的权益分派方案 本公司 2024 年年度权益分派方案为：以公司现有总股本 272,700,161 股为 基数，向全体股东每 10 股派 2.600000 元人民币现金（含税；扣税后，通过深股 通持有股份的香港市场投资者、境外机构（含 QFII、RQFII）以及持有首发前限 售股的个人和证券投资基金每 10 股派 2.340000 元；持有首发后限售股、股权激 励限售股及无限售流通股的个人股息红利税实行差别化税率征收，本公司暂不扣 缴个人所得税，待个人转让股票时，根据其持股期限计算应纳税额【注】；持有 首发后限售股、股权激励限售股及无限售流通股的证券投资基金所涉红利税，对 香港投资者持有基金份额部分按 10%征收，对内地投资者持有基金份额部分实行 差别化税率征收）。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 迪瑞医疗科技股份有限公司（以下简称"公司"） ...

迪瑞医疗(300396.SZ)公告称，持股12.15%的股东恒健国际计划以竞价或大宗交易方式减持公司股份总 数不超过8,148,270股，减持比例不超过公司总股本3%。 ...

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-020 迪瑞医疗科技股份有限公司 关于持股 5%以上股东减持股份预披露公告 持股 5%以上的股东广东恒健国际投资有限公司保证向本公司提供的信 息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 特别提示： 持有迪瑞医疗科技股份有限公司（以下简称"公司"）股份 33,123,600 股 （占公司总股本比例 12.15%）的股东广东恒健国际投资有限公司（以下简称"恒 健国际"）计划以竞价或大宗交易方式减持公司股份总数不超过 8,148,270 股， 减持比例不超过公司总股本 3%，自本减持计划公告之日起十五个交易日后的 90 日内实施。其中通过竞价方式减持的，任意连续 90 个自然日内减持公司股份总 数不超过 2,710,630 股，减持比例不超过公司总股本的 1%；通过大宗交易方式 减持的，任意连续 90 个自然日内减持公司股份不超过 5,437,640 股，减持比例 不超过公司总股本的 2%。 公司近日接到持股 5%以上股东恒健国际的通知，上述股东拟减持公司股票， 现 ...

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [21]. Core Insights - The company reported Q1 2025 revenue of 182 million yuan, a decrease of 72.47% year-on-year, with a net profit of 16 million yuan, down 87.13% [1]. - The company is focusing on optimizing its reagent sales structure, with domestic reagent sales showing improvement and overseas operations remaining stable [7]. - The gross margin improved to 42.78%, up 6.38 percentage points year-on-year, while the net profit margin decreased to 8.59%, down 9.79 percentage points year-on-year due to increased expense ratios [7]. - The company expects a recovery in profits, projecting net profits of 200 million yuan, 260 million yuan, and 330 million yuan for 2025, 2026, and 2027, respectively, with corresponding growth rates of 41.7%, 27.4%, and 28.5% [7]. Financial Summary - Total revenue is projected to grow from 1,218 million yuan in 2024 to 2,018 million yuan in 2027, with year-on-year growth rates of -11.6%, 17.4%, 18.4%, and 19.3% [3]. - The earnings per share (EPS) are expected to increase from 0.52 yuan in 2024 to 1.21 yuan in 2027, with a corresponding price-to-earnings (P/E) ratio decreasing from 25 to 11 [3]. - The company’s total market capitalization is approximately 3.545 billion yuan, with a current share price of 13.00 yuan and a target price of 18.00 yuan [3][4].

迪瑞医疗科技股份有限公司《2025 年第一季度报告》于 2025 年 4 月 26 日 在中国证监会指定的创业板信息披露网站上披露，敬请投资者注意查阅。 特此公告。 迪瑞医疗科技股份有限公司董事会 证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-019 迪瑞医疗科技股份有限公司 2025 年第一季度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 4 月 25 日 ...

Financial Performance - The company's revenue for Q1 2025 was ¥182,424,018.64, a decrease of 72.47% compared to ¥662,535,125.59 in the same period last year[5] - Net profit attributable to shareholders was ¥15,678,683.66, down 87.13% from ¥121,800,597.55 year-on-year[5] - Total operating revenue for the current period was ¥182,424,018.64, a significant decrease of 72.5% compared to ¥662,535,125.59 in the previous period[22] - Net profit for the current period was ¥15,677,203.80, a decrease of 87.1% compared to ¥121,793,477.11 in the previous period[23] - Basic and diluted earnings per share for the current period were both ¥0.0575, down from ¥0.4466 in the previous period[23] Cash Flow - The net cash flow from operating activities improved by 77.33%, reaching -¥41,723,517.67, compared to -¥184,049,664.39 in the previous year[5] - The net cash flow from operating activities was -41,723,517.67, an improvement from -184,049,664.39 in the previous period, indicating a reduction in cash outflow[25] - Cash inflow from operating activities totaled 208,512,287.80, down 27.2% from 286,322,068.49 in the prior period[25] - Cash outflow from operating activities decreased to 250,235,805.47 from 470,371,732.88, reflecting a 46.8% reduction[25] - The net cash flow from investing activities decreased by 116.94%, primarily due to the lack of new financial product purchases[13] - The net cash flow from investing activities was -2,795,904.72, compared to a positive cash flow of 16,503,423.86 in the previous period[25] - Cash inflow from investing activities was only 220.00, significantly lower than 174,288,796.33 in the prior period[25] - Cash outflow from investing activities decreased to 2,796,124.72 from 157,785,372.47, a reduction of 98.2%[25] - The net cash flow from financing activities was -153,126,702.55, worsening from -2,835,595.10 in the previous period[26] - Cash inflow from financing activities was 45,000,000.00, slightly down from 45,151,555.82 in the prior period[26] - Cash outflow from financing activities increased to 198,126,702.55 from 47,987,150.92, a rise of 313.5%[26] - The ending cash and cash equivalents balance was 389,760,256.23, down from 670,694,518.02 in the previous period[26] Assets and Liabilities - The total assets decreased by 6.83% to ¥2,895,358,808.01 from ¥3,107,533,388.27 at the end of the previous year[5] - Total current assets decreased from 1,844,110,841.82 yuan to 1,635,127,222.60 yuan, a decline of approximately 11.3%[19] - Cash and cash equivalents decreased from 586,680,294.87 yuan to 393,260,256.23 yuan, a decline of approximately 33.1%[19] - Total liabilities decreased to ¥825,581,940.55 from ¥1,058,764,060.35, a reduction of 22.0%[21] - The total equity attributable to shareholders of the parent company increased to ¥2,069,765,611.38 from ¥2,048,756,770.93, an increase of 1.0%[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 17,877[15] - The largest shareholder, Shenzhen Huade Xinrun Equity Investment Enterprise, holds 28.34% of shares, totaling 77,288,400 shares, with 45,600,156 shares pledged[15] - Guangdong Hengjian International Investment Co., Ltd. holds 12.15% of shares, totaling 33,123,600 shares[15] Operational Strategy - The company installed over 400 high-speed instruments in the domestic market during the first quarter, indicating a focus on increasing reagent sales[8] - The company adjusted its sales strategy in international markets, particularly focusing on Southeast Asia and Belt and Road Initiative countries[8] - The company plans to enhance operational efficiency by implementing cost-cutting measures and increasing reagent sales[8] Research and Development - Research and development expenses decreased by 34.09% to ¥2,100,000.00, due to optimized project spending[10] - Research and development expenses for the current period were ¥21,117,372.39, a decrease of 34.1% from ¥32,040,993.06 in the previous period[22] - The company has not disclosed any new product or technology developments in the current reporting period[18] Inventory and Receivables - Accounts receivable increased slightly from 441,690,051.18 yuan to 441,722,093.25 yuan[19] - Inventory decreased from 576,420,879.57 yuan to 559,041,927.84 yuan, a decline of approximately 3.0%[19] - Long-term equity investments increased from 450,858,277.53 yuan to 454,373,373.16 yuan[19] Other Financial Metrics - Operating costs decreased by 75.23% to ¥104,000,000.00, reflecting the reduction in revenue[10] - Total operating costs for the current period were ¥174,838,646.92, down 67.1% from ¥532,151,957.58 in the previous period[22] - The company reported a financial expense of -¥7,407,661.00, compared to a financial expense of ¥1,246,558.73 in the previous period, indicating a significant improvement[22] - Other comprehensive income after tax for the current period was ¥5,330,335.74, compared to ¥542,085.22 in the previous period, showing a substantial increase[23]

证券代码：300396 证券简称：迪瑞医疗 公告编号：2025-017 迪瑞医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更前次股东大会决议； 一、会议召开和出席情况 公司于 2025 年 03 月 29 日发出《关于召开 2024 年年度股东大会的通知》 （详见中国证监会指定的创业板信息披露网站 http://www.cninfo.com.cn）。 1、会议召开时间：2025 年 04 月 18 日 14:30 2、会议召开地点：公司会议室 3、会议召开方式：采取现场投票与网络投票相结合的方式。现场会议召开 时间：2025 年 04 月 18 日（星期五）14:30。网络投票时间：2025 年 04 月 18 日。 其中，通过交易系统进行网络投票的时间为：2025 年 04 月 18 日（星期五）9:15— 9:25、9:30-11:30 和 13:00—15:00；通过互联网投票系统投票的具体时间为：2025 年 04 月 ...

致：迪瑞医疗科技股份有限公司（贵公司） 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于迪瑞医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 国枫律股字[2025]A0118号 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2024 年年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则》（以下简称 "《股东大会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法 律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法 律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《迪瑞医疗科技股份 有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、召 集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见书 ...

近期，美国政府宣布对中国输美商品征收"对等关税"，引发市场广泛关注。中国证券报记者采访了解 到，多家医疗器械上市公司已迅速作出反应，表示已有完善预案和应对措施。业内人士指出，尽管关税 政策冲击下产业链影响复杂且存在变数，但长期来看，医疗器械产品自主可控及出海的趋势依然被坚定 看好。 ● 本报记者 傅苏颖 国产化加速 光大证券认为，关税政策变动仍存变数，建议在中美贸易博弈背景下，聚焦高端创新关键领域，关注高 端器械及供应链自主可控，建议重点关注国产替代加速趋势之下市场份额有望提升、受冲击影响较小的 细分领域。 上市公司积极应对 根据中国医药保健品进出口商会数据，2024年，我国对美国的医药贸易出口额为190.47亿美元，其中医 疗器械类达117.58亿美元。中国医药保健品进出口商会日前发布的一则针对美国实施"对等关税"的声明 提及，绝大部分医用耗材、敷料、医疗设备及其零部件、康复用品等产品均受影响，特别是部分产品叠 加美国政府过往无理加税措施，关税已达极高水平。 多家医疗器械企业在接受中国证券报记者采访时表示，美国对等关税政策对公司影响不大，公司已有相 应的预案。 迈瑞医疗相关负责人表示，长期以来，迈瑞医疗密切 ...

迪瑞医疗科技股份有限公司的主营业务是医疗检验仪器及配套试纸试剂的研发、生产、营销与服务。公 司的主要产品是尿液分析、生化分析、化学发光免疫分析、妇科分泌物分析、血细胞分析、凝血分析、 整体化实验室。公司获得的专利213项，其中发明专利136项；已获得软件著作权96项。 4月10日，迪瑞医疗今日收盘13.62元，上涨1.95%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到26.17倍，总市值37.14亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.15倍，行业中值29.13倍，迪瑞医疗排 名第64位。 资金流向方面，4月10日，迪瑞医疗主力资金净流入270.71万元，近5日总体呈流出状态，5日共流出 130.31万元。 最新一期业绩显示，2024年年报，公司实现营业收入12.18亿元，同比-11.63%；净利润1.42亿元，同 比-48.50%，销售毛利率43.84%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)64迪瑞医疗26.1726.171.8137.14亿行业平均 46.1548.384.77102.50亿行业中值29.1329.012.3143.45亿1 ...